Axcess Limited v. Controller Of Patents And Designs

In the high-stakes world of pharmaceutical patents, the line between a permissible amendment and an impermissible overreach can make or break a company's intellectual property. For Axcess Limited, that line became the central battleground in a fight over a patent application covering bile acids and biguanides as protease inhibitors for gut peptides. The lesson for founders and IP professionals is clear: understanding the boundaries of patent amendments is not just legal technicality, it's a survival skill.

Axcess Limited, the applicant, sought protection in India for an invention involving bile acids and biguanides used as protease inhibitors targeting gut peptides. The application, numbered 2427/DELNP/2011, was examined by the Controller of Patents and Designs. During prosecution, Axcess Limited sought to amend its claims, including introducing the concept of the invention as a 'composition as a product.' The Controller, however, refused to allow these amendments, taking the position that the changes went beyond the original scope of what was disclosed. Citing Section 59(1) of the Indian Patent Act, the Controller rejected the application, leaving Axcess Limited with no choice but to escalate the matter to the Delhi High Court.

Axcess Limited argued before the Delhi High Court that the amendments it sought were well within the boundaries of its original complete specification and the PCT claims from which the Indian application was derived. The company contended that a careful reading of the complete specification supported the introduction of the 'composition as a product' framing, and that the Controller had erred in mechanically rejecting the application without conducting the kind of detailed examination the law demands. On the other side, the Controller stood by its position that the amendments expanded the scope beyond what was originally disclosed, effectively introducing new subject matter that should not be permitted under Section 59(1). The legal friction centered on a fundamental question: where does legitimate claim refinement end and impermissible expansion begin?

The Delhi High Court sided with Axcess Limited on this critical point. After a detailed examination of the complete specification, the court found that the amended claims, including those framed as a 'composition as a product,' were supported by the original disclosure. The court held that amendments sought under Section 59(1) are permissible when they fall within the scope of the original complete specification or the PCT claims, even when they introduce new aspects like product composition claims. The rejection by the Controller was set aside, and the matter was remanded back to the Controller for fresh consideration on the merits.

For founders, startup leaders, and IP professionals, this case delivers a powerful reminder: amendments to a patent application are not automatically off-limits just because they introduce a new framing or aspect of the invention. The key test is whether the amended claims find support within the original complete specification or the PCT claims from which the application derives. Before filing or amending, invest time in ensuring your specification is drafted with enough breadth and detail to support future claim variations. And if a rejection comes down on amendment grounds, remember that a thorough, specification-based argument can turn the tide, as Axcess Limited's victory demonstrates.